Shortages will affect non-pen injectable insulins through early weeks of April ... Patients will have a harder time getting ...

'ZDNET Recommends': What exactly does it mean? ZDNET's recommendations are based on many hours of testing, research, and comparison shopping. We gather data from the best available sources ...

"I am pleased that we have extended our cash runway to the end of 2025, with the upcoming $10 million payment of the BioChaperone Lispro milestone. We have maintained the rigorous management of ...

BioChaperone® CagriSema is expected to offer significant manufacturing advantages, such as enabling it to be included in existing multi-use pen platforms, allowing for four weekly injections.

Patients received the FlexPen if they were randomized to the insulin pen group and prescribed any rapid-acting insulin (insulin lispro or insulin aspart) or the combination of 70% insulin aspart ...